Amphastar Pharmaceuticals, Inc. (AMPH)
AMPH Stock Price Chart
Explore Amphastar Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze AMPH price movements and trends.
AMPH Company Profile
Discover essential business fundamentals and corporate details for Amphastar Pharmaceuticals, Inc. (AMPH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
25 Jun 2014
Employees
2.03k
Website
https://www.amphastar.comCEO
Yongfeng Zhang
Description
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
AMPH Financial Timeline
Browse a chronological timeline of Amphastar Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is $0.63, while revenue estimate is $179.71m.
Earnings released on 7 May 2026
EPS came in at $0.42 falling short of the estimated $0.70 by -40.00%, while revenue for the quarter reached $171.17m , missing expectations by -1.32%.
Earnings released on 26 Feb 2026
EPS came in at $0.73 falling short of the estimated $0.90 by -19.16%, while revenue for the quarter reached $183.11m , missing expectations by -3.00%.
Earnings released on 6 Nov 2025
EPS came in at $0.93 surpassing the estimated $0.77 by +20.78%, while revenue for the quarter reached $191.84m , beating expectations by +0.71%.
Earnings released on 7 Aug 2025
EPS came in at $0.85 surpassing the estimated $0.71 by +19.72%, while revenue for the quarter reached $174.41m , missing expectations by -1.52%.
Earnings released on 7 May 2025
EPS came in at $0.74 surpassing the estimated $0.66 by +12.12%, while revenue for the quarter reached $170.53m , missing expectations by -1.46%.
Earnings released on 27 Feb 2025
EPS came in at $0.92 falling short of the estimated $1.01 by -8.91%, while revenue for the quarter reached $186.52m , missing expectations by -1.19%.
Earnings released on 6 Nov 2024
EPS came in at $0.96 falling short of the estimated $0.99 by -3.03%, while revenue for the quarter reached $188.82m , missing expectations by -1.70%.
Earnings released on 7 Aug 2024
EPS came in at $0.94 surpassing the estimated $0.77 by +22.08%, while revenue for the quarter reached $182.39m , beating expectations by +6.70%.
Earnings released on 8 May 2024
EPS came in at $1.04 surpassing the estimated $0.96 by +8.33%, while revenue for the quarter reached $171.84m , missing expectations by -1.65%.
Earnings released on 28 Feb 2024
EPS came in at $0.88 falling short of the estimated $0.93 by -5.38%, while revenue for the quarter reached $178.11m , beating expectations by +1.39%.
Earnings released on 8 Nov 2023
EPS came in at $1.15 surpassing the estimated $0.69 by +66.67%, while revenue for the quarter reached $180.56m , beating expectations by +2.22%.
Earnings released on 8 Aug 2023
EPS came in at $0.65 surpassing the estimated $0.56 by +16.07%, while revenue for the quarter reached $145.71m , beating expectations by +6.07%.
Earnings released on 9 May 2023
EPS came in at $0.62 surpassing the estimated $0.48 by +29.17%, while revenue for the quarter reached $140.02m , beating expectations by +2.71%.
Earnings released on 28 Feb 2023
EPS came in at $0.73 surpassing the estimated $0.41 by +78.05%, while revenue for the quarter reached $135.02m , beating expectations by +6.16%.
Earnings released on 7 Nov 2022
EPS came in at $0.38 falling short of the estimated $0.39 by -2.56%, while revenue for the quarter reached $120.13m , missing expectations by -4.64%.
Earnings released on 8 Aug 2022
EPS came in at $0.39 surpassing the estimated $0.35 by +11.43%, while revenue for the quarter reached $123.47m , beating expectations by +4.56%.
Earnings released on 9 May 2022
EPS came in at $0.47 surpassing the estimated $0.36 by +30.56%, while revenue for the quarter reached $120.37m , beating expectations by +6.21%.
Earnings released on 10 Mar 2022
EPS came in at $0.42 surpassing the estimated $0.36 by +16.67%, while revenue for the quarter reached $120.89m , beating expectations by +8.30%.
Earnings released on 8 Nov 2021
EPS came in at $0.46 surpassing the estimated $0.24 by +91.67%, while revenue for the quarter reached $112.20m , beating expectations by +43.66%.
Earnings released on 9 Aug 2021
EPS came in at $0.21 matching the estimated $0.21, while revenue for the quarter reached $101.66m , beating expectations by +0.28%.
AMPH Stock Performance
Access detailed AMPH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
